Obtained Patent for Oral Administration Drugs Including Dapagliflozin and Taksan
[Asia Economy Reporter Minwoo Lee] Daehwa Pharmaceutical announced on the 14th that it has obtained a patent for an "oral pharmaceutical composition containing taxane."
Hot Picks Today
If They Fail Next Year, Bonus Drops to 97 Million Won... A Closer Look at Samsung Electronics DS Division’s 600M vs 460M vs 160M Performance Bonuses
- Opening a Bank Account in Korea Is Too Difficult..."Over 150,000 Won in Notarization Fees Just for a Child's Account and Debit Card" [Foreigner K-Finance Status]②
- SpaceX Pursues 'Largest Ever' Mega IPO... Profitability of Space Business Still Unclear
- Room Prices Soar from 60,000 to 760,000 Won and Sudden Cancellations: "We Won't Even Buy Water in Busan" — BTS Fans Outraged
- "Who Is Visiting Japan These Days?" The Once-Crowded Tourist Spots Empty Out... What's Happening?
The company explained, "This technology pertains to the currently approved oral paclitaxel anticancer drug 'Liporaxel solution' formulation and oral docetaxel formulation technology, as well as the technology to produce oral taxane (paclitaxel, docetaxel) formulations in capsule form."
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
!["Please Help Us": How Much Do Those Bowing 90 Degrees These Days Actually Earn? [Data Pick]](https://cwcontent.asiae.co.kr/asiaresize/307/2026052010120870131_1779239528.png)
